Menlo Park

DCM Promotes Three New Partners

Retrieved on: 
Wednesday, September 27, 2023
Start-Up, Professional Services, Finance, University, Health, Investment, Weight Watchers, Tempo, Atlas, SME, Columbia Business School, Internet, Digital health, DCM, Menlo Park, Caddy (web server), M.B.A, AI, SoFi, NYSE, Shanghai Jiao Tong University, Software, Creative industries, Venture capital, Fintech, New York University

DCM , a global early-stage venture capital firm, today announced it has internally promoted three new partners within its investment team: David Cheng, Kenichiro Hara, and Fiona Huang.

Key Points: 
  • DCM , a global early-stage venture capital firm, today announced it has internally promoted three new partners within its investment team: David Cheng, Kenichiro Hara, and Fiona Huang.
  • “We look forward to seeing how the next generation of partners helps our portfolio companies become some of the world’s leading technology companies.”
    David joined DCM as an Associate in the Menlo Park Office in September 2014.
  • At DCM, Ken focuses on B2B SaaS and marketplace, consumer facing or SME focused Internet and mobile service, healthcare and Fintech.
  • Ken also contributed to the launch of DCM’s new seed investment program, DCM Atlas, and plays a key role in the program.

Adicet Bio, Inc. Announces Closing of $100 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, December 10, 2021
Guggenheim, U.S. Securities and Exchange Commission, Madison Avenue, LLC, Telephone, Guggenheim Partners, Patient, Sale, CAR, Cancer, Prospectus, GLOBE, Jefferies Group, Jefferies, ACET, Exercise, SEC, Attention, Nasdaq, Floor, Security (finance)

The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $100.6 million.

Key Points: 
  • The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $100.6 million.
  • All of the shares in the offering are were sold by Adicet.
  • Jefferies and Guggenheim Securities acted as joint book-running managers for the offering.
  • Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.

Corcept Therapeutics Announces Extension of Previously Announced Tender Offer

Retrieved on: 
Wednesday, December 8, 2021
Transfer, CORT, GLOBE, Board of directors, Food, Patient, Board, NASDAQ, Regulation of tobacco by the U.S. Food and Drug Administration, Lists of diseases, Pharmaceutical industry, Security (finance)

Based on information provided by Continental Stock Transfer & Trust Company, the depositary for the tender offer, to date, 8,282,336 shares have been tendered for purchase in the tender offer.

Key Points: 
  • Based on information provided by Continental Stock Transfer & Trust Company, the depositary for the tender offer, to date, 8,282,336 shares have been tendered for purchase in the tender offer.
  • Stockholders who have validly tendered and not withdrawn their shares do not need to re-tender their shares or take any other action in response to the extension of the tender offer.
  • The tender offer is also subject to terms and conditions, which are described in detail in the offer to purchase.
  • Except for the extension of the expiration of the tender offer as set forth above, the terms and conditions of the tender offer remain the same.

Talis Biomedical Announces Leadership Transition

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Forward-looking statement, GLOBE, Health equity, EUA, Security (finance), Liquid biopsy, Market development, UCLA Anderson School of Management, Leadership, Private Securities Litigation Reform Act, Food, Trade, Maintenance, COVID-19, Duke University, FDA, DNA sequencing, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Annual report, Risk, Pharmaceutical industry

Mr. Kelley has more than 25 years of leadership experience in the biotechnology industry and has served as the Companys Chief Commercial Officer since September 2020.

Key Points: 
  • Mr. Kelley has more than 25 years of leadership experience in the biotechnology industry and has served as the Companys Chief Commercial Officer since September 2020.
  • Before Talis, Mr. Kelley was Vice President, Sales and Commercial Development of Genalyte, Inc., a healthcare analytics and point-of-care diagnostics company.
  • Talis is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care.
  • The company plans to develop and commercialize innovative products on its sample-to-answer Talis One Test System to enable accurate, low cost, and rapid molecular testing.

Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Jefferies, Floor, GLOBE, Prospectus, SEC, CAR, Exercise, Security (finance), Attention, ACET, Annual report, Private Securities Litigation Reform Act, Patient, Cancer, Form 10-K, Guggenheim, LLC, Jefferies Group, Sale, Nasdaq, Madison Avenue, Telephone, Guggenheim Partners

Adicet also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • Adicet also granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less underwriting discounts and commissions.
  • All of the shares in the offering are to be sold by Adicet.
  • The offering is expected to close on or about December 10, 2021, subject to the satisfaction of customary closing conditions.
  • These forward-looking statements include, but are not limited to, those relating to Adicets expectations regarding the anticipated closing of the public offering.

Robinhood Announces Termination of Resale Registration Statement

Retrieved on: 
Tuesday, December 7, 2021
Robin Hood, Securities Act of 1933, File, GLOBE, IPO, SEC, Security (finance)

MENLO PARK, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Today, Robinhood Markets, Inc. (Robinhood) filed to terminate its registration statement for the resale of Class A common stock received by certain shareholders upon the automatic conversion of Tranche I convertible notes in connection with Robinhoods IPO (the Conversion Shares).

Key Points: 
  • MENLO PARK, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Today, Robinhood Markets, Inc. (Robinhood) filed to terminate its registration statement for the resale of Class A common stock received by certain shareholders upon the automatic conversion of Tranche I convertible notes in connection with Robinhoods IPO (the Conversion Shares).
  • As previously described in Robinhoods October 8, 2021 press release, the registration statement had been filed to register the potential resale of these Conversion Shares into the public markets.
  • Robinhood filed the registration statement pursuant to a pre-existing contractual obligation under the purchase agreement for the Tranche I convertible notes.
  • Accordingly, the termination of the registration statement will not impact the number of shares of Robinhood Class A common stock that can be sold in the public markets.

Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock

Retrieved on: 
Tuesday, December 7, 2021
U.S. Securities and Exchange Commission, Floor, GLOBE, Prospectus, SEC, CAR, Attention, ACET, Annual report, Private Securities Litigation Reform Act, Patient, Cancer, Form 10-K, LLC, Jefferies Group, Sale, Nasdaq, Madison Avenue, Telephone, Guggenheim Partners, Security (finance)

All of the shares in the proposed offering are to be sold by Adicet.

Key Points: 
  • All of the shares in the proposed offering are to be sold by Adicet.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Jefferies LLC and Guggenheim Securities, LLC are acting as joint book-running managers for the proposed offering.
  • These risks and uncertainties related to completion of the proposed public offering on the anticipated terms, or at all, include, but are not limited to, market conditions and the satisfaction of customary closing conditions related to the proposed public offering.

PacBio and UCLA Health Announce Research Collaboration for Whole Genome Sequencing in Rare Diseases

Retrieved on: 
Tuesday, December 7, 2021
Molecule, Genetics, U.S. Securities and Exchange Commission, Pathology, Company, Health, Research, GLOBE, Knowledge, Technology, Security (finance), Disease, Genetic variation, Private Securities Litigation Reform Act, Abraxis BioScience, Patient, DNA, CEO, UCLA Institute for Research on Labor and Employment, Degenerative disease, Biomedical Research, Securities Exchange Act of 1934, UCLA Health, UCLA, WGS, Microbiology, Single-molecule real-time sequencing, David Geffen School of Medicine at UCLA, NASDAQ, Diagnosis, Pacific Biosciences, Whole genome sequencing, Pharmaceutical industry, Medical imaging

MENLO PARK, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and the UCLA Institute for Precision Health and David Geffen School of Medicine at UCLA have formed a research collaboration to further identify the causes of rare diseases.

Key Points: 
  • MENLO PARK, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, and the UCLA Institute for Precision Health and David Geffen School of Medicine at UCLA have formed a research collaboration to further identify the causes of rare diseases.
  • The study will leverage PacBios HiFi long-read sequencing technology for whole genome sequencing (WGS) to look at undiagnosed pediatric rare disease patients who have already been sequenced with short-read technology.
  • For rare disease patients, a genetic diagnosis always provides clarity to the whole family and can mean more effective treatments to avoid long-term complications, explained Nelson.
  • Within our undiagnosed diseases program at UCLA, approximately 50 percent of the rare disease patients we conduct short-read WGS on will still not have a DNA diagnosis.

Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy

Retrieved on: 
Monday, December 6, 2021
Patient, CAR, Senior, University, Safety, MD Anderson Cancer Center, PD, Â, Cytokine release syndrome, CRS, Population, Clinical Lymphoma, Myeloma & Leukemia, Cancer, IL-6, Mantle cell lymphoma, Blood, Flow cytometry, Department, CD19, COVID-19, Cytokine, Gene editing, CD20, Nasdaq, Neoplasm, GLOBE, B-cell lymphoma, Association, DLBCL, ACET, CR, Graft-versus-host disease, Neurotoxicity, Follicular lymphoma, Vaccine, Pharmaceutical industry

We look forward toreporting additional data in the first half of 2022 and to rapidly progressing our pipeline to realize the full potential of our gamma delta CAR T cell platform for patients.

Key Points: 
  • We look forward toreporting additional data in the first half of 2022 and to rapidly progressing our pipeline to realize the full potential of our gamma delta CAR T cell platform for patients.
  • These data suggestthat ADI-001has the potential to be an effective treatment option for B cell malignancies if confirmed in further clinical testing.
  • "As we look to expand into additional cohorts, we plan to leverage our scalable off-the-shelf manufacturing process to meet future needs.
  • We look forward to advancing our novel allogeneic gamma delta T cell pipeline for cancer patients.

PacBio Grants Equity Incentive Award to New Employee

Retrieved on: 
Friday, December 3, 2021
Molecule, Research, Financial compensation, Microbiology, RSU, Pacific Ocean, Genetic variation, Pacific Biosciences, GLOBE, Effective date, Option, Abraxis BioScience, Single-molecule real-time sequencing, Biomedical Research, NASDAQ

The options have an exercise price of $23.06 per share, which is equal to the closing price of PacBio common stock on November 29, 2021 (the Effective Date).

Key Points: 
  • The options have an exercise price of $23.06 per share, which is equal to the closing price of PacBio common stock on November 29, 2021 (the Effective Date).
  • The option grant and the award of RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the award agreements entered into with the employee.
  • Cited in thousands of peer-reviewed publications, PacBio sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
  • For more information, please visit www.pacb.com and follow @PacBio .